Use of a Plasticizer for Physical Stability Prediction of Amorphous Solid Dispersions
Source abstract
Abstract
Utilizing glycerol as a plasticizer, an accelerated physical stability testing method of amorphous solid dispersions (ASDs) was developed. The influence of glycerol concentration on the glass transition temperature and α-relaxation time (a measure of molecular mobility) of amorphous ketoconazole, celecoxib, and the solid dispersions of each prepared with polyvinylpyrrolidone was investigated. By temperature scaling ( T g / T ), the effects of glycerol concentration and temperature on the relaxation time were simultaneously evaluated. Glycerol, in a concentration dependent manner, accelerated crystallization in all of the systems without affecting the fragility. In celecoxib-PVP ASDs, the drug crystallization was well coupled to molecular mobility and was essentially unaltered at glycerol concentrations up to 2% w/w. The acceleration in crystallization brought about by glycerol expedited the determination of the coupling between molecular mobility and crystallization. As a result, we were able to predict the physical stability of the unplasticized ASD. This approach is especially useful for ASDs with high polymer content where drug crystallization is extremely slow at the relevant storage temperature.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Polymer crystallization and properties · Microfluidic and Capillary Electrophoresis Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, University of Minnesota, Minneapolis, Minnesota 55455, United States
Funding
Pharmaceutical Research and Manufacturers of America Foundation · University of Minnesota · William and Mildred Peters Endowment Fund, University of Minnesota
References (35)
Show source-provided references
1. 10.1016/j.ejps.2015.05.01510.1016/j.ejps.2015.05.015 ↗
2. 10.1016/j.drudis.2007.09.00510.1016/j.drudis.2007.09.005 ↗
3. 10.1016/j.ijpharm.2011.08.03210.1016/j.ijpharm.2011.08.032 ↗
4. 10.1063/1.48075210.1063/1.480752 ↗
5. 10.1002/jps.2092610.1002/jps.20926 ↗
6. 10.1021/mp300487u10.1021/mp300487u ↗
7. 10.1021/mp500800c10.1021/mp500800c ↗
8. 10.1021/acs.molpharmaceut.5b0033310.1021/acs.molpharmaceut.5b00333 ↗
9. 10.1021/acs.cgd.6b0071410.1021/acs.cgd.6b00714 ↗
10. 10.1021/acs.molpharmaceut.5b0095010.1021/acs.molpharmaceut.5b00950 ↗
11. 10.1021/acs.molpharmaceut.6b0021810.1021/acs.molpharmaceut.6b00218 ↗
12. 10.1016/S0008-6215(00)00227-510.1016/S0008-6215(00)00227-5 ↗
13. 10.1021/js960048410.1021/js9600484 ↗
14. 10.1021/mp900228310.1021/mp9002283 ↗
15. 10.1021/ma951073j10.1021/ma951073j ↗
16. Kremer F. · 200310.1007/978-3-642-56120-7 ↗
17. 10.1016/j.ijpharm.2006.08.01010.1016/j.ijpharm.2006.08.010 ↗
18. 10.1021/jf980697w10.1021/jf980697w ↗
19. 10.1007/s11095-005-7626-910.1007/s11095-005-7626-9 ↗
20. 10.1021/ma60061a02110.1021/ma60061a021 ↗
21. 10.1063/1.43379810.1063/1.433798 ↗
22. 10.1023/A:101894181074410.1023/A:1018941810744 ↗
23. 10.1021/mp500514610.1021/mp5005146 ↗
24. 10.1126/science.267.5206.192410.1126/science.267.5206.1924 ↗
25. 10.1063/1.46611710.1063/1.466117 ↗
26. 10.1007/s11095-009-9970-710.1007/s11095-009-9970-7 ↗
27. 10.1002/jps.1016910.1002/jps.10169 ↗
28. 10.1002/jps.2052210.1002/jps.20522 ↗
29. 10.1007/s11095-006-9079-110.1007/s11095-006-9079-1 ↗
30. 10.1002/jps.2116210.1002/jps.21162 ↗
31. 10.1002/jps.2223210.1002/jps.22232 ↗
32. 10.1021/mp500229d10.1021/mp500229d ↗
33. 10.1021/bm100506810.1021/bm1005068 ↗
34. 10.1007/s11483-007-9030-y10.1007/s11483-007-9030-y ↗
35. 10.1021/acs.molpharmaceut.5b0085310.1021/acs.molpharmaceut.5b00853 ↗